The thyroid gland located in the anterior neck secretes thyroid hormones. It is essential for multiple metabolic functions spanning almost every organ system. Hypothyroidism results from low levels of thyroid hormone. It has varied etiology and manifestations. Clinicians treat hypothyroidism with levothyroxine. Untreated hypothyroidism increases morbidity and mortality. This article reviews etiology, clinical presentation, diagnosis, and management of hypothyroidism.
The most common etiology is iodine deficiency in iodine-deficient geographic areas worldwide. Autoimmune thyroid diseases are the leading cause of hypothyroidism in the United States and the iodine-sufficient regions. Etiology can be influenced locally by iodine fortification and emergence of new iodine-deficient areas.
Other common causes of hypothyroidism are drugs such as amiodarone and lithium, thyroid radioactive iodine therapy or thyroid surgery, radiotherapy to head or neck area, and central hypothyroidism from neoplastic, infiltrative, inflammatory, or iatrogenic disorders of the pituitary or hypothalamus.
The NHANESIII (National Health and Nutrition Examination Survey) study found the prevalence of overt hypothyroidism among US adults (12 years of age and older) to be 0.3% and subclinical hypothyroidism 4.3%. Female gender and increasing age were associated with higher thyroid-stimulating hormone (TSH) and prevalence of antithyroid antibodies.
The hypothalamus secretes thyrotropin-releasing hormone (TRH) that stimulates the pituitary gland to produce thyroid-stimulating hormone (TSH). Thyroid-stimulating hormone stimulates the thyroid gland to produce and secrete mainly T4 while T3 is produced mainly by conversion of T4 to T3. Levels of T3 and T4, in turn, exert a negative feedback on the production of TRH and TSH. Alteration in structure and function of any of these organs or pathways can result in hypothyroidism.
It is important to maintain a high index of suspicion for hypothyroidism since the signs and symptoms can be mild and nonspecific and different symptoms may be present in different patients.
Inquire about dry skin, voice changes, hair loss, constipation, fatigue, muscle cramps, cold intolerance, sleep disturbances, menstrual cycle abnormalities, weight gain, galactorrhea. Also obtain a complete medical, surgical, medication and family history.
History of adverse pregnancy and neonatal outcomes should also be sought.
Patients can also present with carpal tunnel syndrome, sleep apnea, hyponatremia, Hypercholesterolemia, congestive heart failure, and prolonged QT interval.
A physical examination may reveal an enlarged thyroid gland, the presence of nodules, prolonged ankle reflex relaxation time, hoarse voice, and skin and hair changes.
Serum TSH level is used to screen for primary hypothyroidism in most patients. In overt hypothyroidism, TSH levels are elevated, and free T4 levels are low. In subclinical hypothyroidism, TSH levels are elevated, and free T4 levels are normal.
Central hypothyroidism is of pituitary or hypothalamic origin. TSH produced can be biologically inactive and can affect the levels of bioactive TSH, hence diagnosis of central hypothyroidism should be based on free T4 rather than TSH.
Labs should include evaluation for autoimmune thyroid diseases with levels of anti-thyroid antibodies: the thyroid peroxidase antibodies and anti-thyroglobulin antibodies. Particularly in patients with thyroid nodules, fine-needle aspiration biopsy should be considered.
Patients with subclinical hypothyroidism and thyroid peroxidase antibody positivity have a greater risk of developing overt hypothyroidism and should be followed up periodically with clinical evaluation and lab tests for the same.
T3 levels are not a reliable or recommended test. Hospitalized patients should undergo TSH testing only when thyroid dysfunction is suspected.
On labs, hyperlipidemia, elevated serum CK, elevated hepatic enzymes, anemia can be present.
BUN, creatinine, and uric acid levels can also be elevated.
Hypothyroidism is mainly treated with levothyroxine monotherapy.
Thyroid replacement treatment can exacerbate co-existing adrenal insufficiency. Patients with known or suspected adrenal insufficiency should be tested and treated for the adrenal insufficiency while awaiting results. Adrenal insufficiency can also be associated with subclinical hypothyroidism that is reversible with treatment of adrenal insufficiency. In patients who have confirmed adrenal insufficiency consider a reassessment of thyroid tests following adequate treatment of adrenal insufficiency.
Replacement levothyroxine dose is 1.6 mcg/kg per day, should be taken 60 minutes before a meal and at least 3 hours post-meal which makes before breakfast or at bedtime the practical times for most patients. Maintaining a consistent formulation or brand of levothyroxine is important.
When switching to the intravenous (IV) form, reduce the dose to 70% of the oral dose. Malabsorption syndromes, medications such as sucralfate, calcium preparations, and bile acid sequestrants can interfere with the absorption of levothyroxine.
Based on the 2012 Clinical Practice Guidelines for Hypothyroidism in Adults by American Association of Clinical Endocrinologists and the American Thyroid Association, therapy should be monitored and titrated based on TSH measurements. Serum free T4 can also be used. Labs should be drawn every 4 to 8 weeks until target levels are achieved after starting the treatment, after any dose changes, changes in formulation or brand of levothyroxine, after starting or stopping of any medications that may affect levels. If stable, then monitoring interval can be extended to 6 months, and if stable then, further monitoring can be extended to 12 months or can be done at shorter intervals on a case-to-case basis along with clinical evaluation. Central hypothyroidism should be monitored based on free T4 rather than TSH.
For elderly patients and patients with cardiac diseases, starting at a lower dose and titrating slowly is recommended. Patients with cardiac disease should be monitored for the development of any symptoms of angina. Monitor for side effects of treatment such as atrial fibrillation and osteoporosis.
Effective treatment should achieve a clinical improvement of signs and symptoms, along with an improved sense of patient well-being and normal TSH (or free T4 levels as applicable).
A comprehensive differential diagnosis workup is recommended for unresolved symptoms in the presence of biochemical euthyroidism. There is a lack of strong evidence supporting the routine inclusion of triiodothyronine (T3) preparations with levothyroxine in the treatment of hypothyroidism.
If symptoms persist despite normalization of TSH/free T4 levels, then consultation with an endocrinologist should also be considered.
Differential diagnosis is based on signs and symptoms; for example, fatigue can point to iron deficiency anemia, sleep apnea, depression, and rheumatological diseases.
Myxedema coma is a presentation of severe hypothyroidism and is an endocrine emergency. Early recognition and prompt treatment in the intensive care unit (ICU) is essential, and even then, mortality reaches 25% to 60%.
Myxedema crisis should be suspected in patients that have encephalopathy, hypothermia, seizures, severe hyponatremia, hypoglycemia, cardiogenic shock and arrhythmias, respiratory failure, and manifestations of fluid retention. A combination of a few or all of these manifestations and other symptoms of mild to severe hypothyroidism as stated above can be present.
Factors leading to an increased risk of myxedema crisis include inadequate doses of thyroid hormone, interruption in treatment, undiagnosed hypothyroidism, or presence of acute illness such as sepsis  perhaps due to increased metabolic demands.
Supportive treatment should be provided in the intensive care unit with fluid and electrolyte management, ventilator support, vasopressors, treatment of coexisting acute illness, and hypothermia.
Thyroid replacement treatment is with intravenous hydrocortisone at stress doses followed by intravenous levothyroxine then switched to oral levothyroxine after clinical improvement. If effective, this should result in cardiopulmonary and cognitive improvement. There should also be an associated improvement in laboratory derangements including a down trending of TSH which should be measured every 1 to 2 days during the initial treatment period. Intravenous liothyronine (T3) can be considered until initial improvement.
Endocrinology consultation should be considered.
Hypothyroidism affects multiple organ systems across all age groups and affects patient well-being and ability to function on a daily basis. Treatment is with levothyroxine monotherapy (Grade A, Best Evidence Level 1).
Effective treatment calls for a team-based and patient-centered approach. When patient symptoms are not adequately controlled an endocrinology consult should be obtained.
Endocrinology consultation is also recommended in complex scenarios such as preconception, pregnancy, congenital and pediatric hypothyroidism, failure of treatment, co-existing cardiac or other endocrine disorders, difficulty in interpretation of thyroid test results, drug-induced hypothyroidism. Other specialists that may be needed are a psychiatrist, obstetrician-gynecologist, pediatrician, cardiologist, and intensivist.
It is helpful to work closely with a pharmacist to determine medication and food interactions, the effect of changes in levothyroxine formulations, to investigate the causes for the requirement of unusually high doses of levothyroxine or fluctuating TSH levels. Prompt notification of unusually high levels of TSH by laboratory personnel, close monitoring of vital signs and mental status by nurses can facilitate early treatment and better outcomes, especially in the inpatient setting such as in myxedema coma. Rapid response teams can be effectively utilized when hypothyroidism causes hemodynamic instability.
|||Global epidemiology of hyperthyroidism and hypothyroidism., Taylor PN,Albrecht D,Scholz A,Gutierrez-Buey G,Lazarus JH,Dayan CM,Okosieme OE,, Nature reviews. Endocrinology, 2018 May [PubMed PMID: 29569622]|
|||Garber JR,Cobin RH,Gharib H,Hennessey JV,Klein I,Mechanick JI,Pessah-Pollack R,Singer PA,Woeber KA, Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Thyroid : official journal of the American Thyroid Association. 2012 Dec [PubMed PMID: 22954017]|
|||Hollowell JG,Staehling NW,Flanders WD,Hannon WH,Gunter EW,Spencer CA,Braverman LE, Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). The Journal of clinical endocrinology and metabolism. 2002 Feb [PubMed PMID: 11836274]|
|||Anand A,Singh KR,Kushwaha JK,Hussain N,Sonkar AA, Papillary Thyroid Cancer and Hashimoto's Thyroiditis: An Association Less Understood. Indian journal of surgical oncology. 2014 Sep [PubMed PMID: 25419066]|
|||Hou J,Yu P,Zhu H,Pan H,Li N,Yang H,Jiang Y,Wang L,Wang B,Wang Y,You L,Chen S, The impact of maternal hypothyroidism during pregnancy on neonatal outcomes: a systematic review and meta-analysis. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology. 2016 [PubMed PMID: 26527131]|
|||Samuels MH, Psychiatric and cognitive manifestations of hypothyroidism. Current opinion in endocrinology, diabetes, and obesity. 2014 Oct [PubMed PMID: 25122491]|
|||Khalid S,Asad-Ur-Rahman F,Abbass A,Gordon D,Abusaada K, Myxedema Ascites: A Rare Presentation of Uncontrolled Hypothyroidism. Cureus. 2016 Dec 5 [PubMed PMID: 28083456]|
|||Zare-Khormizi MR,Rahmanian M,Pourrajab F,Akbarnia S, Massive pericardial effusion and rhabdomyolysis secondary to untreated severe hypothyroidism: the first report. Acta clinica Belgica. 2014 Oct [PubMed PMID: 25056490]|
|||Saini V,Yadav A,Arora MK,Arora S,Singh R,Bhattacharjee J, Correlation of creatinine with TSH levels in overt hypothyroidism - a requirement for monitoring of renal function in hypothyroid patients? Clinical biochemistry. 2012 Feb [PubMed PMID: 22061337]|
|||Jonklaas J,Bianco AC,Bauer AJ,Burman KD,Cappola AR,Celi FS,Cooper DS,Kim BW,Peeters RP,Rosenthal MS,Sawka AM, Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement. Thyroid : official journal of the American Thyroid Association. 2014 Dec [PubMed PMID: 25266247]|
|||Abdullatif HD,Ashraf AP, Reversible subclinical hypothyroidism in the presence of adrenal insufficiency. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2006 Sep-Oct [PubMed PMID: 17002934]|
|||Guglielmi R,Frasoldati A,Zini M,Grimaldi F,Gharib H,Garber JR,Papini E, ITALIAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS STATEMENT-REPLACEMENT THERAPY FOR PRIMARY HYPOTHYROIDISM: A BRIEF GUIDE FOR CLINICAL PRACTICE. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2016 Nov [PubMed PMID: 27482609]|
|||Current evidence for the treatment of hypothyroidism with levothyroxine/levotriiodothyronine combination therapy versus levothyroxine monotherapy., Hennessey JV,Espaillat R,, International journal of clinical practice, 2018 Feb [PubMed PMID: 29381251]|
|||Mathew V,Misgar RA,Ghosh S,Mukhopadhyay P,Roychowdhury P,Pandit K,Mukhopadhyay S,Chowdhury S, Myxedema coma: a new look into an old crisis. Journal of thyroid research. 2011 [PubMed PMID: 21941682]|